Peter Gage pursued the novel approach of targeting the viroporin protein instead of the more common approach of targeting the spike protein as a means of fighting viral infections, certainly an interesting idea. However the recent failure of the BIT225 / Covid trial, in which BIT225 showed no increased efficacy over the placebo tends to suggest that BIT225 is virtually useless. This is an important result because it is hard to now think there will be a different result against the HiV, why would there be?, they are both viruses. Even more of a stretch to think BIT225 would have any effect on cancer cells:
BIT Price at posting:
2.0¢ Sentiment: None Disclosure: Not Held
